Onconetix, Inc. (ONCO)

0.1235 +0.0105 (+9.29%) At close: 04:00PM EDT

Onconetix, Inc.

201 East Fifth Street
Suite 1900
Cincinnati, OH 45202
United States
513 620 4101
https://onconetix.gcs-web.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 12

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Bruce Harmon	Chief Financial Officer	349.38k	N/A	1958
Dr. Ralph Schiess Ph.D.	Interim CEO & Chief Science Officer	N/A	N/A	1979
Dr. Brian Price Ph.D.	Head of Technology Strategy	126.48k	N/A	N/A
Mr. Frank A. Jaeger M.A., M.B.A.	Senior VP of Marketing & Business Development	N/A	N/A	1970
Mr. Andrew D. Skibo Ph.D.	Global Head of Biologics Operations	N/A	N/A	N/A
Mr. Theodore Scott Yoho	Head of Business Development	N/A	N/A	N/A
Dr. Ali I. Fattom Ph.D.	Head of Science & Discovery	N/A	N/A	N/A
Dr. Jay Newmark M.B.A., M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Christian Bruhlmann	Chief Strategy Officer & GM of Europe	N/A	N/A	1977
Dr. Donald L. Very Jr., Ph.D.	Senior VP of Commercial Research & Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Corporate Governance

Onconetix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.